AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for...
- Open
- 0.2580
- High
- 0.2759
- Low
- 0.2400
- Prev. Close
- 0.2547
- Volume
- 757.64K
- Turnover
- 193.43K
- Avg Price
- 0.2553
- Bid/Ask Ratio
- -98.02%
- Amplitude
- 14.10%
- 52wk High
- 1.4500
- Volume Ratio
- 1.88
- Turnover Ratio
- 7.72%
AEON Biopharma, Inc. Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$1.43495.24%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · 5 hours ago
13:33 ETAEON Launches Agentic Checkout, Powered by AI Card for Autonomous Commerce
- Unusual Whales · Aug 31 at 12:02 PM
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
- PUBT · Aug 24 at 12:03 PM
AEON Biopharma names former FDA neuroscience leader Paul Lee acting chief regulatory officer
- PUBT · Aug 21 at 11:41 PM
AEON Biopharma 10% owner Timothy P. Lynch buys 1,150,000 shares for $243,455
